KOSDAQBiotech & Pharma038070

SeouLinBioscienceCO

₩3,445▲ 0.44%2026-11-18 close
Market Cap
₩32B
Turnover
₩44,486,930
Volume
10K
Shares out.
9.3M
PER
19.6×
PBR
0.4×
EPS
₩173
Dividend Yield
2.95%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩100 per share · Prices as of the 2026-11-18 close

01

Report overview

Quarterly profit recovers as the business shifts toward services and manufacturing

SeouLinBioscienceCO returned to operating profit in the third quarter of 2026, but annual profitability has stayed well below 2022 levels, so the payoff from its shift toward services and manufacturing is the next thing to verify.

  1. 1

    Third-quarter 2026 revenue was KRW 25.1 billion, up 9.7% year on year, and operating profit was KRW 2.09 billion, up 166.4% year on year.

  2. 2

    The operating margin fell from 8.4% in 2022 to 0.9% in 2025, and operating profit declined for three consecutive years from 2023 to 2025.

  3. 3

    Net profit attributable to controlling shareholders was KRW 732 million in 2025, down 74.9% year on year, while net profit including non-controlling interests was KRW 574 million.

  4. 4

    Expansion is under way, with the 100% acquisition of Staon Medical in March 2026, the launch of the POCUS omics analysis service in February 2026, and the official launch of an immunoassay service with Levity in June 2026.

  5. 5

    The debt-to-equity ratio rose from 16.9% in 2024 to 38.1% in 2025, and of the KRW 86.1 billion total equity at the end of 2025, KRW 84.2 billion belonged to controlling shareholders.

02

Business structure

SeouLinBioscienceCO was founded in 1984 and has provided total solutions for biological research and production, growing around domestic instrument localization, molecular diagnostics and healthcare.

Its roots lie in distributing research instruments and reagents, and it supplies core product lines of a global analytical instrument maker to domestic research labs. On top of that sits its own analysis service brand, POCUS.

In February 2026 it launched an omics service that analyzes about 7,000 proteins from a single blood draw, and in June 2026 it officially launched a highly sensitive immunoassay service developed with the global life science company Levity.

Researchers can send samples and study objectives without buying expensive instruments, which points to a shift from selling instruments and reagents toward higher-value research support that includes analysis outsourcing and data interpretation.

In March 2026 the company secured 100% of Staon Medical, a skin-care medical device maker, and made it a wholly owned subsidiary; management describes this as a vertical structure linking R&D, production and global distribution.

Environmental and hygiene equipment, such as the EcoTree-L sterilizing water unit, also sits in its product range.

Unlike large biologics contract manufacturers or global instrument makers, it is a small-to-mid-sized distributor and service provider that differentiates through custom analysis for domestic research clients and its own platform.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩22.9B₩800M3.4%
2025Q4₩20B₩100M0.7%
2026Q1₩19.5B₩200M0.9%
2026Q2₩20.8B-₩600M−2.9%
2026Q3₩25.1B₩2.1B8.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩102.4B₩8.6B₩9.5B8.4%11.4%53.0%
2023₩89.6B₩2.5B-₩100M2.8%−0.1%33.9%
2024₩75.4B₩1B₩2.9B1.3%3.5%16.9%
2025₩77.1B₩700M₩700M0.9%0.9%38.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Based on the filed annual results, revenue went from KRW 102.4 billion in 2022 to KRW 89.6 billion in 2023 (down 12.5% year on year) and KRW 75.4 billion in 2024 (down 15.8%), then edged up to KRW 77.1 billion in 2025 (up 2.2%). Among 2022 to 2025, 2022 was the largest year and 2024 the smallest.

Profitability fell faster than sales.

Operating profit went from KRW 8.58 billion in 2022 to KRW 2.49 billion in 2023 (down 70.9%), KRW 953 million in 2024 (down 61.8%) and KRW 692 million in 2025 (down 27.4%), declining for three consecutive years from 2023 to 2025, and the operating margin dropped from 8.4% in 2022 to 0.9% in 2025.

Management attributed the 2025 operating decline to higher cost of sales. Net profit attributable to controlling shareholders went from KRW 9.54 billion in 2022 to a net loss of KRW 118 million in 2023, turned to a profit of KRW 2.91 billion in 2024, and was KRW 732 million in 2025 (down 74.9%).

Net profit including non-controlling interests was KRW 574 million in 2025, and the company cited fair value gains and losses on investment securities and derivatives as a drag.

Quarterly revenue was KRW 22.9 billion in the third quarter of 2025, KRW 20 billion in the fourth quarter (down 12.7% from the prior quarter), KRW 19.5 billion in the first quarter of 2026, then KRW 20.8 billion in the second quarter and KRW 25.1 billion in the third quarter (up 20.6% from the prior quarter), rising for two consecutive quarters.

Operating profit went from KRW 175 million in the first quarter of 2026 to an operating loss of KRW 597 million in the second quarter, then back to KRW 2.09 billion in the third quarter, up 166.4% year on year.

Net profit attributable to controlling shareholders reached KRW 1.38 billion in the third quarter, up 80.4% year on year, and the sum over the latest four quarters was KRW 1.53 billion.

The second quarter showed an operating loss yet a positive controlling-shareholder profit of KRW 342 million, which points to a possible non-operating effect, though the filed figures alone do not settle the cause. Operating cash flow swung from -KRW 4.61 billion in 2024 to KRW 4.76 billion in 2025.

05

Industry analysis

Domestic bioresearch support demand moves with research institute budgets and the investment flow into biotech ventures, which drives demand for instruments and reagents.

The company's post-2022 earnings decline is attributed to the shift from the pandemic-era boom to endemic conditions, a view also reflected in a financial information site's summary of the first half of 2025.

Management cited higher cost of sales as the reason operating profit fell, and for a distribution-centered business, profit margins tend to depend on how quickly cost increases are passed on to prices.

On the demand side, there is an expectation that raw material and analysis needs will grow as domestic biopharmaceutical pipelines move from clinical trials into production, but figures showing that this trend has translated into SeouLinBioscienceCO's sales are not yet clear.

Within the same biopharma sector, large manufacturers such as Samsung Biologics compete on scale, while SeouLinBioscienceCO is weighted toward instrument distribution and analysis services and operates on a different axis.

Compared with technology-driven listed peers, its revenue base is smaller and its model rests on services and distribution rather than a proprietary drug pipeline.

In medical aesthetic devices, the Staon Medical acquisition gives it manufacturing capacity, but it must compete with established global players on overseas approvals and distribution networks. In sterilizing water equipment, it overlaps with larger disinfection and water treatment companies.

06

Outlook

The direction management has outlined is expansion of its research support platform. According to a June 2026 report, the POCUS platform is widening its service scope into an integrated research support platform combining omics analysis, immunoassays and AI-based data interpretation.

Because the immunoassay service with Levity operates as a certified analysis service center model, researchers can use highly sensitive analysis without buying instruments.

After the Staon Medical acquisition, the company said it plans to expand its medical aesthetic device lineup and strengthen overseas approvals and distribution networks to widen its reach into global healthcare markets.

CEO Kang Mi-ok presented a plan to grow into an integrated platform company spanning bio, diagnostics and medical aesthetics. At the regular shareholders meeting on March 26, 2026, the agenda approving the 32nd fiscal year financial statements and consolidated statements passed.

For this direction to show up in earnings, service revenue and manufacturing revenue need to become visible as separate lines in quarterly results, which can be checked in the revenue breakdown of the next regular report.

Whether the swing from a second-quarter operating loss to a third-quarter profit reflects service expansion or temporary cost reductions can be separated only through changes in the cost structure across quarters.

The integrated platform direction itself is confirmed in disclosures, but its contribution to earnings is not yet clearly visible in figures.

07

Valuation

PER
19.6×
PBR
0.4×
ROE
1.8%
EPS
₩173
BPS
₩9,653
Dividend per share
₩100

The price-to-book ratio has moved below 1x at quarter-end points in the past and currently sits well below 1x. A large discount to net asset value is linked to the fact that the KRW 84.2 billion controlling-shareholder equity, out of KRW 86.1 billion total equity, serves as the asset value reference.

By contrast, the price-to-earnings multiple is sensitive to small changes in earnings, since net profit attributable to controlling shareholders over the latest four quarters totals only KRW 1.53 billion.

Years of sharp swings, such as the 2023 net loss and the 74.9% drop in 2025, mean that historical earnings-based multiples are not a stable reference point. The company has a dividend history, but its capacity to pay depends on controlling-shareholder profit and cash flow.

The return to positive operating cash flow in 2025 is a useful reference for gauging investment and dividend capacity. When reading valuation, a factual comparison is framed best by looking at how consistently earnings hold up quarter by quarter, alongside the multiple level itself.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Quarterly profit recovery

Third-quarter 2026 operating profit reached KRW 2.09 billion, up 166.4% year on year, and net profit attributable to controlling shareholders reached KRW 1.38 billion, up 80.4%. Revenue has risen for two consecutive quarters starting in the second quarter of 2026, moving away from the first-quarter low.

Profit has stayed positive since the fourth-quarter 2025 controlling-shareholder net loss of KRW 356 million, which shows earnings capacity recovering quarter by quarter.

Expansion from instrument distribution into services and manufacturing

In February 2026 the POCUS platform introduced a service that analyzes about 7,000 proteins from a single blood sample, and in June 2026 it officially launched an immunoassay service with Levity. The company defines these as higher-value research support services.

With Staon Medical brought in during March 2026, manufacturing-based revenue could add to diversification of the income structure.

Cash flow turnaround and equity base

Operating cash flow swung from -KRW 4.61 billion in 2024 to KRW 4.76 billion in 2025. Of the KRW 86.1 billion total equity at the end of 2025, KRW 84.2 billion belongs to controlling shareholders, a sizable equity base. With the price-to-book ratio far below 1x, the share price can be read against asset value.

09

Bear factors

Long-term decline in profitability

Revenue fell from KRW 102.4 billion in 2022 to KRW 77.1 billion in 2025, and the operating margin dropped from 8.4% to 0.9%. Operating profit declined for three consecutive years from 2023 to 2025.

Management pointed to higher cost of sales as the reason for the 2025 decline, and that cost burden could limit any recovery in margins.

Earnings volatility and fair value effects

Net profit attributable to controlling shareholders swung from a KRW 118 million loss in 2023 to a 74.9% drop in 2025. Fair value changes in investment securities and derivatives weighed on 2025 net profit.

The second quarter of 2026 recorded an operating loss of KRW 597 million, showing how quickly quarterly profit can turn negative.

Rising leverage and transition burden

The debt-to-equity ratio rose from 16.9% in 2024 to 38.1% in 2025, and total liabilities at the end of 2025 stood at KRW 32.7 billion. Securing 100% of Staon Medical and preparing overseas approvals bring investment and integration burdens.

With net profit attributable to controlling shareholders over the latest four quarters at KRW 1.53 billion, integration costs could absorb a meaningful share of earnings.

10

Risk factors

Earnings volatility

Profit attributable to controlling shareholders went from a loss in 2023 to a profit in 2024 and a sharp decline in 2025, and the second quarter of 2026 still posted an operating loss. Net profit moves differently from core operating profit because of fair value gains and losses. With thin quarterly profits, small cost changes can shift the earnings trend.

Execution of the business transition

Integrating Staon Medical and expanding the POCUS platform require different capabilities in manufacturing, regulatory approval and service operations. Overseas approvals and distribution networks are tasks without a fixed timetable. If service and manufacturing revenue are not shown separately, judging the results becomes difficult.

Research demand cycle

Revenue is sensitive to research institute budgets and biotech investment flows. The decline in sales since 2022 is explained by demand adjustment after the shift to endemic conditions. Revenue edged up to KRW 77.1 billion in 2025, but there is not yet enough evidence to conclude that demand has recovered.

11

What to watch next

  1. January to February 2027 (timing not fixed)

    If a preliminary fourth-quarter 2026 result is disclosed, check whether the third-quarter profit recovery carried into the fourth quarter. Preliminary figures precede audited results and should be read separately.

  2. Late March 2027 (filing deadline for the 2026 annual report)

    The 2026 annual report will show whether the operating margin recovers from 0.9% in 2025 and how the debt-to-equity ratio moves from 38.1%. This is the next regular report and includes fourth-quarter 2026 results.

  3. Ad hoc disclosures (timing not fixed)

    Track how much the POCUS analysis service and the Levity immunoassay service contribute to revenue. If service revenue is not disclosed separately, changes in the revenue mix in quarterly reports serve as an indirect check.

  4. Ad hoc disclosures (timing not fixed)

    Watch for news on overseas approvals for Staon Medical and expansion of its medical aesthetic lineup. How quickly manufacturing revenue shows up in consolidated results will indicate the integration effect.

12

Overall view

SeouLinBioscienceCO showed a quarterly profit recovery in the third quarter of 2026, with revenue of KRW 25.1 billion and operating profit of KRW 2.09 billion. Annual operating margin, however, fell from 8.4% in 2022 to 0.9% in 2025, and operating profit declined for three consecutive years from 2023 to 2025.

With net profit attributable to controlling shareholders down to KRW 732 million in 2025 and fair value swings moving net profit, the durability of quarterly earnings is the key variable.

On the business side, the shift from instrument distribution toward services and manufacturing is visible in disclosures through the POCUS analysis service, the Levity immunoassay service and the Staon Medical acquisition.

On the financial side, operating cash flow turned positive in 2025, but the debt-to-equity ratio rose to 38.1% from 16.9% in 2024. Valuation shows a price-to-book ratio far below 1x, while the earnings multiple is sensitive given the small base of the latest four quarters.

The next checkpoints are whether the operating margin recovers in the 2026 annual report and how much service revenue contributes.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. thevc.kr
  2. comp.fnguide.com
  3. moneypie.net
  4. saramin.co.kr
  5. vegannews.co.kr
  6. hankyung.com
  7. m.news.nate.com
  8. m.news.nate.com
  9. biotimes.co.kr
  10. m.news.nate.com
  11. edaily.co.kr
  12. edaily.co.kr
  13. edaily.co.kr
  14. m.news.nate.com
  15. tradingview.com
  16. menafn.com
  17. judal.co.kr
  18. judal.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis